U.S. markets open in 2 hours 37 minutes
  • S&P Futures

    3,819.25
    -23.25 (-0.61%)
     
  • Dow Futures

    30,628.00
    -214.00 (-0.69%)
     
  • Nasdaq Futures

    13,493.50
    +8.00 (+0.06%)
     
  • Russell 2000 Futures

    2,112.40
    -33.40 (-1.56%)
     
  • Crude Oil

    52.64
    +0.03 (+0.06%)
     
  • Gold

    1,837.60
    -13.30 (-0.72%)
     
  • Silver

    25.17
    -0.37 (-1.46%)
     
  • EUR/USD

    1.2123
    -0.0046 (-0.38%)
     
  • 10-Yr Bond

    1.0400
    0.0000 (0.00%)
     
  • Vix

    25.59
    +2.40 (+10.35%)
     
  • GBP/USD

    1.3706
    -0.0026 (-0.19%)
     
  • USD/JPY

    103.8350
    +0.2080 (+0.20%)
     
  • BTC-USD

    31,125.74
    -1,176.62 (-3.64%)
     
  • CMC Crypto 200

    625.74
    -14.18 (-2.22%)
     
  • FTSE 100

    6,602.54
    -51.47 (-0.77%)
     
  • Nikkei 225

    28,635.21
    +89.03 (+0.31%)
     

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Sale of Cellular Biomedicine Group, Inc. - CBMG

Newsfile Corp.
·2 min read

New York, New York--(Newsfile Corp. - August 12, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:

To: All Persons or Entities who purchased Cellular Biomedicine Group, Inc. ("Cellular Biomedicine" or the "Company") (NASDAQ: CBMG) stock prior to August 12, 2020.

You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Cellular Biomedicine to a consortium that includes members of Cellular Biomedicine management and several entities that collectively hold approximately 51.5% of the outstanding Cellular Biomedicine shares. Under the terms of the merger, Cellular Biomedicine stockholders will receive $19.75 in cash for each outstanding share of common stock held immediately prior to the effective time of the merger. To learn more about the action and your rights, go to:

https://www.zlk.com/mna2/cellular-biomedicine-group-inc-information-request-form

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. There is no cost or obligation to you.

The Cellular Biomedicine merger investigation concerns whether the Board of Cellular Biomedicine has harmed stockholders by agreeing to enter into this transaction and whether all material facts have been properly disclosed to stockholders.

Levi & Korsinsky is a nationally recognized firm with offices in New York, Connecticut, California, and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities lawsuits and have recovered hundreds of millions of dollars for aggrieved shareholders. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/61576